9,451 Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by VestGen Advisors LLC

VestGen Advisors LLC decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 72.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,675 shares of the biotechnology company’s stock after selling 9,451 shares during the quarter. VestGen Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $241,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 9.5% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 5,594 shares of the biotechnology company’s stock worth $366,000 after buying an additional 483 shares during the last quarter. Evergreen Capital Management LLC grew its stake in Arrowhead Pharmaceuticals by 42.2% in the 3rd quarter. Evergreen Capital Management LLC now owns 8,601 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 2,554 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 9.2% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,565 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 384 shares during the period. Washington Trust Advisors Inc. raised its holdings in Arrowhead Pharmaceuticals by 179.9% in the 3rd quarter. Washington Trust Advisors Inc. now owns 73,281 shares of the biotechnology company’s stock valued at $4,796,000 after acquiring an additional 47,096 shares during the period. Finally, Inspire Investing LLC raised its holdings in Arrowhead Pharmaceuticals by 477.0% in the 3rd quarter. Inspire Investing LLC now owns 10,981 shares of the biotechnology company’s stock valued at $719,000 after acquiring an additional 9,078 shares during the period. 62.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ARWR. Piper Sandler restated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. Morgan Stanley increased their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Finally, Citigroup assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They set a “buy” rating and a $108.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Insider Buying and Selling

In other news, Director Adeoye Y. Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $61.65 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $37.06 and a 52 week high of $95.49. The firm has a market cap of $8.68 billion, a price-to-earnings ratio of -27.40 and a beta of 1.34. The firm’s 50-day simple moving average is $68.15 and its 200 day simple moving average is $71.55. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.26) EPS. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.